Mirodenafil

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mirodenafil
Mirodenafil.svg
Legal status
Legal status
  • US: Unscheduled; not FDA-approved
  • Rx-only (KR)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C26H37N5O5S
Molar mass 531.666 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Mirodenafil belongs to the drug class PDE5 inhibitors, which includes avanafil, sildenafil, tadalafil, udenafil, and vardenafil, and is the first-line treatment for erectile dysfunction. Developed by SK Chemicals Life Science, mirodenafil is marketed in Korea under the trade name Mvix, offered both as tablets (50 mg and 100 mg) and as orally dissolving film (50 mg).

Several clinical trials were conducted,[1][2][3] but mirodenafil has not been approved for use in the United States by the U.S. Food and Drug Administration.

References[edit]

  1. ^ Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG (November 2008). "Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction". The Journal of Sexual Medicine. 5 (11): 2672–80. PMID 18638004. doi:10.1111/j.1743-6109.2008.00945.x. 
  2. ^ Kim BH, Yi S, Kim J, Lim KS, Kim KP, Lee B, Shin SG, Jang IJ, Yu KS (June 2009). "Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea". Clinical Therapeutics. 31 (6): 1234–43. PMID 19695390. doi:10.1016/j.clinthera.2009.06.008. 
  3. ^ Shin KH, Kim BH, Kim TE, Kim JW, Yi S, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS (December 2009). "The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study". Clinical Therapeutics. 31 (12): 3009–20. PMID 20110038. doi:10.1016/j.clinthera.2009.12.012.